Louise Roulin

A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma

Emmanuel Bachy, Steven Le Gouill, Roberta Di Blasi et al. · Nature Medicine · 2022 · 343 citations · Full text

High total metabolic tumor volume at baseline predicts survival independent of response to therapy

Laëtitia Vercellino, Anne‐Ségolène Cottereau, Olivier Casasnovas et al. · Blood · 2020 · 176 citations · Full text

Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients

Nicole Wong Doo, Carole Soussain, Sylvain Choquet et al. · UCL Discovery (University College London) · 2022 · 76 citations

Rituximab plus gemcitabine and oxaliplatin (R-GemOx) in refractory/relapsed diffuse large B-cell lymphoma: a real-life study in patients ineligible for autologous stem-cell transplantation

Clarisse Cazelles, Karim Belhadj, Hélène Vellemans et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2021 · 43 citations · Full text

Cell Therapy, R/r Dlbcl, Immunology +18

Lenalidomide maintenance for diffuse large B‐cell lymphoma patients responding to R‐CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study

Catherine Thiéblemont, Susannah Howlett, Olivier Casasnovas et al. · British Journal of Haematology · 2019 · 17 citations · Full text

Elderly Patients, Cancer Management, Surgery +16